	US 12,453,707 B2
	Vaginal films
Lisa Cencia Rohan, Pittsburgh, PA (US)
Assigned to UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed on Sep. 13, 2023, as Appl. No. 18/367,869.
Application 18/367,869 is a continuation of application No. 16/494,804, granted, now 11,793,765, previously published as PCT/US2018/024505, filed on Mar. 27, 2018.
Claims priority of provisional application 62/573,437, filed on Oct. 17, 2017.
Claims priority of provisional application 62/477,164, filed on Mar. 27, 2017.
Prior Publication US 2024/0099986 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/70 (2006.01); A61K 9/00 (2006.01); A61K 31/505 (2006.01); A61K 31/675 (2006.01); A61K 47/10 (2017.01); A61K 47/38 (2006.01); A61P 31/18 (2006.01)

CPC A61K 9/7007 (2013.01) [A61K 9/0031 (2013.01); A61K 9/0034 (2013.01); A61K 31/505 (2013.01); A61K 31/675 (2013.01); A61K 47/10 (2013.01); A61K 47/38 (2013.01); A61P 31/18 (2018.01)]

9 Claims

1. A dissolvable film formed from an aqueous solution comprising 6% wt. hydroxyethyl cellulose, 6% wt. hydroxypropyl methyl cellulose, 2% wt. carboxymethyl cellulose, 0.5 to 2.4% wt. of a plasticizer, and a nucleoside reverse transcriptase inhibitor and lacking polyvinyl pyrrolidone, wherein said plasticizer is glycerin, and wherein said film comprises 10 mg or more of said nucleoside reverse transcriptase inhibitor as the only pharmaceutically active agent of said film.